MCID: HPT014
MIFTS: 49

Hepatorenal Syndrome

Categories: Gastrointestinal diseases, Liver diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hepatorenal Syndrome

MalaCards integrated aliases for Hepatorenal Syndrome:

Name: Hepatorenal Syndrome 12 74 20 54 44 15 71 32
Hepato-Renal Syndrome 20

Classifications:



External Ids:

Disease Ontology 12 DOID:11823
ICD9CM 34 572.4
MeSH 44 D006530
NCIt 50 C113400
SNOMED-CT 67 51292008
ICD10 32 K76.7
UMLS 71 C0019212

Summaries for Hepatorenal Syndrome

GARD : 20 Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. As many as 40% of individuals with cirrhosis and ascites will develop hepatorenal syndrome. Symptoms may include fatigue, abdominal pain, and a general feeling of ill health (malaise). There are two distinct types of hepatorenal syndrome. Type I progresses quickly (within days), leading to kidney failure. Individuals with type I typically have dramatically reduced urine output, edema, and jaundice, and often suffer from hepatic encephalopathy. Type II progresses more slowly, over weeks or months, and the symptoms are less severe. The cause of hepatorenal syndrome is unknown. A contributing factor seems to be a narrowing of the blood vessels that connect into the kidneys. This causes a decrease in blood flow to the kidneys, impairing their function. In some cases, triggers or precipitating factors (infections, blood loss from the gastrointestinal tract, low blood pressure) are involved. Treatment is aimed at helping the liver work better and maintaining kidney function. In many cases, a liver transplant is needed. In some cases, individuals also need a kidney transplant.

MalaCards based summary : Hepatorenal Syndrome, also known as hepato-renal syndrome, is related to peritonitis and hepatic coma. An important gene associated with Hepatorenal Syndrome is ALB (Albumin), and among its related pathways/superpathways are Oxytocin signaling pathway and cAMP signaling pathway. The drugs Norfloxacin and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and neutrophil, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 An acute kidney failure that is characterized by severe renal vasoconstriction.

Wikipedia : 74 Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of... more...

Related Diseases for Hepatorenal Syndrome

Diseases related to Hepatorenal Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 387)
# Related Disease Score Top Affiliating Genes
1 peritonitis 31.0 IL18 F2 AQP1 ALB
2 hepatic coma 30.9 GPT F2 ALB
3 portal hypertension 30.9 GPT F2 EDN1 ALB ACE
4 acute liver failure 30.9 GPT F2 ALB
5 alcoholic hepatitis 30.7 IL18 GPT F2 ALB
6 hepatic encephalopathy 30.6 IL18 GPT F2 ALB
7 esophageal varix 30.4 GPT F2 ALB
8 uremia 30.4 REN ALB ACE
9 bilirubin metabolic disorder 30.4 GPT F2 ALB
10 alcoholic liver cirrhosis 30.3 GPT F2 ALB
11 end stage renal disease 30.3 REN CST3 ALB ACE
12 hepatitis a 30.3 GPT F2 ALB
13 proteinuria, chronic benign 30.3 REN NAGLU ALB ACE
14 cholecystitis 30.3 GPT F2 ALB
15 active peptic ulcer disease 30.1 F2 ALB
16 peliosis hepatis 30.1 GPT F2
17 viral hepatitis 30.0 GPT F2 ALB
18 obstructive jaundice 30.0 REN GPT F2 EDN1 ALB
19 pulmonary edema 30.0 REN NPPA F2 EDN1 ACE
20 hydrops, lactic acidosis, and sideroblastic anemia 29.9 NPPA AQP1 ALB
21 compartment syndrome 29.9 LCN2 GPT F2 ALB
22 cholangitis 29.9 GPT F2 ALB
23 biliary tract disease 29.9 GPT F2 ALB
24 deficiency anemia 29.9 NPPA LCN2 CST3 ALB ACE
25 hepatitis e 29.9 GPT F2 ALB
26 interstitial nephritis 29.8 REN EDN3 ALB ACE
27 biliary atresia 29.8 GPT F2 ALB
28 sclerosing cholangitis 29.8 GPT F2 ALB
29 visceral leishmaniasis 29.8 IL18 CST3 ALB
30 eclampsia 29.8 REN F2 EDN1 ALB ACE
31 liver cirrhosis 29.8 REN NPY NPPA GPT F2 EDN1
32 cholangitis, primary sclerosing 29.8 GPT F2 ALB
33 autoimmune hepatitis 29.7 GPT F2 ALB
34 anuria 29.7 REN LCN2 F2 CST3 ALB ACE
35 intestinal obstruction 29.7 GPT EDN3 ALB
36 iga glomerulonephritis 29.7 REN NAGLU ALB ACE
37 leptospirosis 29.6 LCN2 IL18 F2 AQP1
38 kidney disease 29.6 REN NPPA NAGLU LCN2 IL18 EDN1
39 metabolic acidosis 29.6 GPT F2 AQP2 ALB
40 acute kidney failure 29.4 REN NPPA LCN2 IL18 GPT F2
41 pyelonephritis 29.3 NAGLU LCN2 GPT ALB ACE
42 acute kidney tubular necrosis 29.3 REN NPPA NAGLU LCN2 IL18 GPT
43 thrombocytopenia 29.1 IL18 GPT F2 EDN1 ALB
44 pre-eclampsia 29.1 REN NPPA IL18 F2 EDN1 CST3
45 chronic kidney disease 28.8 REN NPY NPPA LCN2 IL18 EDN1
46 pulmonary hypertension 28.7 REN NPY NPPA F2 EDN3 EDN1
47 peroxisome biogenesis disorder 1a 11.3
48 arima syndrome 11.2
49 liver disease 10.8
50 zellweger syndrome 10.4

Comorbidity relations with Hepatorenal Syndrome via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alcoholic Liver Cirrhosis
Deficiency Anemia Heart Disease
Hepatic Encephalopathy Portal Hypertension

Graphical network of the top 20 diseases related to Hepatorenal Syndrome:



Diseases related to Hepatorenal Syndrome

Symptoms & Phenotypes for Hepatorenal Syndrome

GenomeRNAi Phenotypes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.23 IL18 LCN2 REN
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.23 ACE AQP1 IL18 LCN2 REN

MGI Mouse Phenotypes related to Hepatorenal Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.15 ACE ALB AQP1 AVPR1A CST3 EDN1
2 homeostasis/metabolism MP:0005376 10.13 ACE ALB AQP1 AQP2 AVPR1A CST3
3 mortality/aging MP:0010768 10.03 ACE ALB AQP1 AQP2 CST3 EDN1
4 muscle MP:0005369 9.76 ALB AVPR1A CST3 EDN1 F2 IL18
5 nervous system MP:0003631 9.7 ACE AQP1 AVPR1A CST3 EDN1 EDN3
6 renal/urinary system MP:0005367 9.32 ACE ALB AQP1 AQP2 EDN1 LCN2

Drugs & Therapeutics for Hepatorenal Syndrome

Drugs for Hepatorenal Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norfloxacin Approved Phase 4 70458-96-7 4539
2 Anti-Infective Agents Phase 4
3 Cytochrome P-450 Enzyme Inhibitors Phase 4
4 Antibiotics, Antitubercular Phase 4
5 Anti-Bacterial Agents Phase 4
6
Norepinephrine Approved Phase 3 51-41-2 439260
7
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
8
tannic acid Approved Phase 2, Phase 3 1401-55-4
9
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
10 Pharmaceutical Solutions Phase 2, Phase 3
11
Alprostadil Approved, Investigational Phase 2 745-65-3 149351 5280723
12
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
13
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
14 Ifetroban Investigational Phase 2 143443-90-7
15 Vitamins Phase 2
16 Mitogens Phase 2
17 Antiviral Agents Phase 2
18 Angiotensinogen Phase 2
19 Giapreza Phase 2
20 Serine Proteinase Inhibitors Phase 2
21 HIV Protease Inhibitors Phase 2
22
protease inhibitors Phase 2
23
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
24
Terlipressin Approved, Investigational 14636-12-5 72081
25
Pentoxifylline Approved, Investigational 6493-05-6 4740
26 Anti-Inflammatory Agents
27 Anti-Inflammatory Agents, Non-Steroidal
28 diuretics
29 Antihypertensive Agents
30 Platelet Aggregation Inhibitors
31 Angiogenesis Inducing Agents
32 Protective Agents
33 Radiation-Protective Agents
34 Antioxidants
35 Phosphodiesterase Inhibitors
36 Vasodilator Agents

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
2 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
3 Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit. Completed NCT03455322 Phase 4 norepinephrine versus midodrine & octreotide
4 Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis Completed NCT00359853 Phase 4 Oral norfloxacin
5 Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study Suspended NCT00287664 Phase 4 terlipressin
6 Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality Terminated NCT02034279 Phase 4 Albumin
7 Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study. Unknown status NCT00742690 Phase 2, Phase 3 terlipressin given by intravenous boluses and albumin;terlipressin given by continuous intravenous infusion and albumin
8 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1 Completed NCT00089570 Phase 3 terlipressin;Placebo
9 Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study Completed NCT00370253 Phase 3 Terlipressin;Noradrenalin
10 A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study) Completed NCT02770716 Phase 3 Terlipressin
11 The Use of Midodrine, Octreotide and Albumin in Refractory Ascites Completed NCT00240045 Phase 2, Phase 3 Midodrine, albumin, octreotide LAR;midodrine, octreotide, albumin
12 Phase 3, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (REVERSE Trial) Completed NCT01143246 Phase 3 Terlipressin;Placebo
13 NORADRENALINE VERSUS TERLIPRESSIN IN THE TREATMENT OF TYPE 2 HEPATORENAL SYNDROME:A RANDOMIZED STUDY Completed NCT01637454 Phase 3 Noradrenaline;Terlipressin
14 Comparison of The Effectiveness of Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1 Recruiting NCT03822091 Phase 3 Terlipressin;Terlipressin and Noradrenaline
15 A Multi-Center, Open Label, Collaborative Research Study to Treat HRS-AKI Patients With Continuous Terlipressin Infusion Recruiting NCT04460560 Phase 3 Terlipressin
16 Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome (HRS): An Open Multicentric Randomized Study Terminated NCT00742339 Phase 2, Phase 3 Terlipressin plus albumin;Midodrine plus octreotide plus human albumin
17 Effect of Administration of Intravenous Albumin and Oral Midodrine on Renal Function in Patients With Cirrhosis and Functional Renal Impairment Completed NCT01133795 Phase 2 Midodrine plus Albumin
18 A Prospective Open Label Control Study to Evaluate the Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure Completed NCT01254994 Phase 2 entecavir;Traditional comprehensive medical treatment
19 An Exploratory Study of FE999908 in Patients With Hepatorenal Syndrome Type 1 Completed NCT01373606 Phase 1, Phase 2 Terlipressin
20 A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome Completed NCT01436500 Phase 2 Ifetroban Injection;Placebo
21 Prospective Pilot Study Assessing Safety and Efficacy of Single Pass Albumin Dialysis in Patients With Acute on Chronic Liver Failure Completed NCT00764049 Phase 1, Phase 2
22 Angiotensin 2 as a Novel Treatment for Hepatorenal Syndrome Not yet recruiting NCT04048707 Phase 2 Angiotensin II;Midodrine;Octreotide;Albumin solution
23 Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Withdrawn NCT01587222 Phase 2 Albumin;Midodrine;Octreotide
24 A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome Terminated NCT01906307 Phase 1 LJPC-501
25 Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients Unknown status NCT02434445
26 Kidney Biomarkers for the Prediction of Response to Terlipressin and Survival in Cirrhotic Patients With Acute Kidney Injury: Multicenter, Prospective Cohort Study Unknown status NCT03530761
27 Urinary Biomarker NGAL in Decompensated Cirrhosis: Early Prediction of AKI and of Treatment Response Unknown status NCT02049125
28 Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury Completed NCT02097784
29 Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Acute Kidney Injury Completed NCT04522297 Midodrine/Octreotide;Nor-epinephrine
30 Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome Associated With Sepsis Completed NCT01932151 Terlipressin and albumin
31 Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg Completed NCT02789150 Early Phase 1 Norepinephrine (Levophed);Norepinephrine (Levophed)
32 Monitoring Plasma and Hemodynamic Markers in Patients Undergoing Liver Resection to Identify Pathophysiological Mechanisms and Predict Clinical Outcome Completed NCT01700231
33 ''To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure' Completed NCT02573727 Nor adrenaline + albumin;Terlipressin + albumin
34 RAI & HRS: Relationship Between Relative Adrenal Insufficiency and Failure of Treatment in Hepatorenal Syndrome: A Prospective Pilot Study Completed NCT04273750
35 MR-flow to Validate Hemodynamic Effect of Terlipressin in Patients With Acute Hepatorenal Syndrome: Can MRI and Echocardiography Predict the Pharmacological Response and Longterm Effect of Terlipressin? Recruiting NCT03483272
36 Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure- A Randomized Open Label Study. Recruiting NCT04416282 Terlipressin
37 Non-invasive Evaluation of the Predictive Value of CEUS and SWE in Patients With and Without TIPS With ACLF, Renal Failure and Hepatorenal Syndrome Not yet recruiting NCT04446858
38 Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome Terminated NCT00734136
39 Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study Terminated NCT02123576 Pentoxyfylline;Placebo;AMO Therapy
40 A Randomised, Open Label Study to Compare the Efficacy of Nor Adrenaline and Terlipressin vs Step up Terlipressin Therapy in Hepatorenal Syndrome Withdrawn NCT01649037 nor adrenaline and terlipressin;step up terlipressin therapy

Search NIH Clinical Center for Hepatorenal Syndrome

Cochrane evidence based reviews: hepatorenal syndrome

Genetic Tests for Hepatorenal Syndrome

Anatomical Context for Hepatorenal Syndrome

MalaCards organs/tissues related to Hepatorenal Syndrome:

40
Liver, Kidney, Neutrophil, Skin, Brain, Bone Marrow, Adipocyte

Publications for Hepatorenal Syndrome

Articles related to Hepatorenal Syndrome:

(show top 50) (show all 2412)
# Title Authors PMID Year
1
Balancing volume resuscitation and ascites management in cirrhosis. 54 61
20124894 2010
2
Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies. 61 54
20124895 2010
3
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. 61 54
19877168 2010
4
Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. 61 54
19238094 2009
5
Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. 61 54
19413694 2009
6
Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature. 54 61
19918689 2009
7
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. 54 61
18492024 2009
8
Management of hepatorenal syndrome. 54 61
18539334 2008
9
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. 61 54
18471512 2008
10
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. 61 54
17939047 2008
11
Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. 61 54
17886336 2008
12
Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. 61 54
18197961 2008
13
Ascites in cirrhosis: a review of management and complications. 54 61
17890787 2007
14
[Hepatorenal syndrome: pathogenesis and treatment]. 61 54
17760404 2007
15
Possible increased risk of pulmonary edema in patients with hepatorenal syndrome on adding octreotide to albumin / noradrenaline therapies. 61 54
17496406 2007
16
Role of endothelin and endothelin receptor antagonists in renal disease. 54 61
16919017 2006
17
The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit. 54 61
16543796 2006
18
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. 61 54
16393283 2006
19
Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. 61 54
16393223 2005
20
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. 54 61
16123966 2005
21
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. 54 61
16108036 2005
22
Preoperative optimization of patients with liver disease. 61 54
16534358 2005
23
The use of albumin in patients with decompensated cirrhosis: the case in favor. 54 61
15729966 2005
24
Hepatorenal syndrome: a dreaded complication of end-stage liver disease. 61 54
15667508 2005
25
[Role of albumin in the treatment of hepatorenal syndrome in cirrhosis]. 61 54
15710088 2005
26
[Advances in therapy for ascites and hepatorenal syndrome]. 61 54
15650969 2005
27
Reconsidering hepatorenal syndrome. Throw in the towel? Not so fast! 61 54
15620124 2004
28
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. 54 61
15239086 2004
29
Terlipressin and albumin combination treatment in hepatorenal syndrome. 54 61
15244209 2003
30
Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. 61 54
14563190 2003
31
Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. 61 54
12867805 2003
32
Terlipressin and albumin for the hepatorenal syndrome. 61 54
12668990 2003
33
Albumin versus crystalloid therapy in the management of hepatorenal syndrome: a model for using meta analysis in cost effectiveness studies and the design of clinical trials. 61 54
14728474 2003
34
Hepatorenal syndrome. 54 61
15094702 2003
35
Review article: albumin for circulatory support in patients with cirrhosis. 61 54
12423450 2002
36
Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction. 61 54
12425489 2002
37
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. 61 54
12297842 2002
38
Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. 54 61
12143045 2002
39
[The use of albumin infusion in decompensated liver cirrhosis]. 61 54
11899505 2002
40
Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. 54 61
11778928 2001
41
[Clinical study on hepatitis D virus-positive patients died from severe hepatitis B]. 61 54
11509140 2001
42
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. 54 61
10905585 2000
43
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. 61 54
10827226 2000
44
Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation. 61 54
11052272 2000
45
Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. 54 61
10728802 2000
46
Acute renal failure associated with liver disease in India: etiology and outcome. 54 61
11041294 2000
47
Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis. 61 54
10638019 1999
48
Serum endothelin and atrial natriuretic peptide in cirrhotic patients with ascites and hepatorenal syndrome. 54 61
9830237 1998
49
Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. 61 54
9425914 1998
50
Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. 61 54
9007721 1996

Variations for Hepatorenal Syndrome

Expression for Hepatorenal Syndrome

Search GEO for disease gene expression data for Hepatorenal Syndrome.

Pathways for Hepatorenal Syndrome

Pathways related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.91 NPPA EDN3 EDN1 AVPR1A
2 11.59 NPY NPPA EDN3 EDN1
3 10.94 REN NPPA EDN3 EDN1 AQP1 ACE

GO Terms for Hepatorenal Syndrome

Cellular components related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 NAGLU LCN2 GPT F2 CST3 AQP2
2 extracellular region GO:0005576 9.7 REN NPY NPPA LCN2 IL18 F2
3 extracellular space GO:0005615 9.4 REN NPY NPPA LCN2 IL18 GPT

Biological processes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.81 NPPA F2 CST3 ALB
2 vasoconstriction GO:0042310 9.61 EDN3 EDN1
3 water transport GO:0006833 9.61 AQP2 AQP1
4 response to muscle stretch GO:0035994 9.6 NPPA EDN1
5 amyloid-beta metabolic process GO:0050435 9.59 REN ACE
6 positive regulation of renal sodium excretion GO:0035815 9.58 EDN1 AVPR1A
7 positive regulation of systemic arterial blood pressure GO:0003084 9.58 AVPR1A ACE
8 inositol phosphate-mediated signaling GO:0048016 9.57 EDN3 EDN1
9 angiotensin maturation GO:0002003 9.56 REN ACE
10 artery smooth muscle contraction GO:0014824 9.55 EDN3 EDN1
11 positive regulation of hormone secretion GO:0046887 9.54 EDN3 EDN1
12 glycerol transport GO:0015793 9.52 AQP2 AQP1
13 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.49 EDN3 EDN1
14 positive regulation of prostaglandin-endoperoxide synthase activity GO:0060585 9.48 EDN3 EDN1
15 peptide hormone secretion GO:0030072 9.46 EDN3 EDN1
16 vein smooth muscle contraction GO:0014826 9.43 EDN3 EDN1
17 cellular response to mercury ion GO:0071288 9.4 AQP2 AQP1
18 cellular response to water deprivation GO:0042631 9.37 AVPR1A AQP2
19 regulation of vasoconstriction GO:0019229 9.33 EDN3 EDN1 ACE
20 nitric oxide transport GO:0030185 9.32 EDN1 AQP1
21 renal water transport GO:0003097 9.26 AQP2 AQP1
22 positive regulation of heart rate GO:0010460 9.26 NPPA EDN3 EDN1 AVPR1A
23 regulation of blood pressure GO:0008217 9.02 REN NPY NPPA EDN1 ACE

Molecular functions related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.46 NPY NPPA EDN3 EDN1
2 water channel activity GO:0015250 9.4 AQP2 AQP1
3 water transmembrane transporter activity GO:0005372 9.37 AQP2 AQP1
4 endothelin B receptor binding GO:0031708 9.32 EDN3 EDN1
5 glycerol transmembrane transporter activity GO:0015168 9.26 AQP2 AQP1
6 signaling receptor binding GO:0005102 9.1 REN NPY NPPA F2 EDN3 EDN1
7 enterobactin binding GO:1903981 8.96 LCN2 ALB

Sources for Hepatorenal Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....